LU87079A1 - Hydrosols de substances pharmacologiquement actives et compositions pharmaceutiques les contenant - Google Patents

Hydrosols de substances pharmacologiquement actives et compositions pharmaceutiques les contenant Download PDF

Info

Publication number: LU87079A1
Authority: LU; Luxembourg
Prior art keywords: hydrosol; active substance; cyclosporine; particles; phase
Prior art date: 1986-12-19

Application number

LU87079A

Other languages

English (en)

French (fr)

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-12-19

Filing date

1987-12-17

Publication date

1988-07-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6316557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU87079(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1987-12-17 Application filed by Sandoz Sa filed Critical Sandoz Sa

1988-07-14 Publication of LU87079A1 publication Critical patent/LU87079A1/fr

Links

239000013543 active substance Substances 0.000 title claims description 63
239000008194 pharmaceutical composition Substances 0.000 title claims description 18
239000008131 herbal destillate Substances 0.000 title description 11
239000002245 particle Substances 0.000 claims description 63
229960001265 ciclosporin Drugs 0.000 claims description 62
229930182912 cyclosporin Natural products 0.000 claims description 62
108010036949 Cyclosporine Proteins 0.000 claims description 59
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 58
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
239000000084 colloidal system Substances 0.000 claims description 19
239000012071 phase Substances 0.000 claims description 18
239000000725 suspension Substances 0.000 claims description 17
239000012736 aqueous medium Substances 0.000 claims description 15
108010010803 Gelatin Proteins 0.000 claims description 13
238000009826 distribution Methods 0.000 claims description 13
239000008273 gelatin Substances 0.000 claims description 13
229920000159 gelatin Polymers 0.000 claims description 13
235000019322 gelatine Nutrition 0.000 claims description 13
235000011852 gelatine desserts Nutrition 0.000 claims description 13
238000000034 method Methods 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 12
239000007787 solid Substances 0.000 claims description 12
239000001856 Ethyl cellulose Substances 0.000 claims description 9
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 9
235000019325 ethyl cellulose Nutrition 0.000 claims description 9
229920001249 ethyl cellulose Polymers 0.000 claims description 9
239000003381 stabilizer Substances 0.000 claims description 7
238000001990 intravenous administration Methods 0.000 claims description 6
239000003960 organic solvent Substances 0.000 claims description 6
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims description 4
238000004108 freeze drying Methods 0.000 claims description 4
230000000144 pharmacologic effect Effects 0.000 claims description 4
230000006641 stabilisation Effects 0.000 claims description 4
238000011105 stabilization Methods 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
239000008346 aqueous phase Substances 0.000 claims description 2
229940102223 injectable solution Drugs 0.000 claims description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
239000000243 solution Substances 0.000 description 24
108010036941 Cyclosporins Proteins 0.000 description 16
229930105110 Cyclosporin A Natural products 0.000 description 15
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 10
229950009702 darodipine Drugs 0.000 description 10
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 9
229960004427 isradipine Drugs 0.000 description 9
239000002105 nanoparticle Substances 0.000 description 9
150000001875 compounds Chemical class 0.000 description 7
239000000203 mixture Substances 0.000 description 7
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
229930195725 Mannitol Natural products 0.000 description 6
239000012153 distilled water Substances 0.000 description 6
239000000594 mannitol Substances 0.000 description 6
235000010355 mannitol Nutrition 0.000 description 6
238000003756 stirring Methods 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
-1 2,1, 3-benzoxadiazol-4-yl Chemical group 0.000 description 5
238000001802 infusion Methods 0.000 description 5
210000002381 plasma Anatomy 0.000 description 5
JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 5
229960002466 proquazone Drugs 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000004807 desolvation Methods 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000007788 liquid Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
229940030600 antihypertensive agent Drugs 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
108010040781 dihydrocyclosporin D Proteins 0.000 description 2
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000003058 plasma substitute Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
241000223205 Coccidioides immitis Species 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
101150071725 SMDT1 gene Proteins 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000884 anti-protozoa Effects 0.000 description 1
230000000842 anti-protozoal effect Effects 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000013475 authorization Methods 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
229950000210 beclometasone dipropionate Drugs 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000011362 coarse particle Substances 0.000 description 1
201000003486 coccidioidomycosis Diseases 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000011243 crosslinked material Substances 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
229960003657 dexamethasone acetate Drugs 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960001347 fluocinolone acetonide Drugs 0.000 description 1
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000010247 heart contraction Effects 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
231100000417 nephrotoxicity Toxicity 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
230000029305 taxis Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Nanotechnology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LU87079A 1986-12-19 1987-12-17 Hydrosols de substances pharmacologiquement actives et compositions pharmaceutiques les contenant LU87079A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3643392		1986-12-19
DE3643392		1986-12-19

Publications (1)

Publication Number	Publication Date
LU87079A1 true LU87079A1 (fr)	1988-07-14

Family

ID=6316557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87079A LU87079A1 (fr)	1986-12-19	1987-12-17	Hydrosols de substances pharmacologiquement actives et compositions pharmaceutiques les contenant

Country Status (25)

Country	Link
US (1)	US5389382A (de)
JP (1)	JP2617958B2 (de)
KR (1)	KR960005136B1 (de)
AT (1)	AT397914B (de)
BE (1)	BE1000848A3 (de)
CA (1)	CA1308656C (de)
CH (1)	CH679451A5 (de)
DD (1)	DD281344A5 (de)
DE (1)	DE3742473C2 (de)
DK (2)	DK173319B1 (de)
ES (1)	ES2028492A6 (de)
FR (1)	FR2608427B1 (de)
GB (1)	GB2200048B (de)
GR (1)	GR871938B (de)
HU (1)	HU205861B (de)
IE (1)	IE61179B1 (de)
IL (1)	IL84855A (de)
IT (1)	IT1230118B (de)
LU (1)	LU87079A1 (de)
MY (1)	MY102037A (de)
NL (1)	NL194638C (de)
NZ (1)	NZ222964A (de)
PT (1)	PT86399B (de)
SE (1)	SE503020C2 (de)
ZA (1)	ZA879533B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4826689A (en) *	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5399363A (en) *	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
DE4140185C2 (de) *	1991-12-05	1996-02-01	Alfatec Pharma Gmbh	Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140179C2 (de) *	1991-12-05	1995-12-21	Alfatec Pharma Gmbh	Akutform für ein Ibuprofen enthaltendes Arzneimittel
DK0615445T3 (da) *	1991-12-05	1996-06-03	Alfatec Pharma Gmbh	Farmaceutisk administrerbar nanosol og fremgangsmåde til fremstilling deraf
DE4140195C2 (de) *	1991-12-05	1994-10-27	Alfatec Pharma Gmbh	Pharmazeutisch applizierbares Nanosol und Verfahren zu seiner Herstellung
DE4140194C2 (de) *	1991-12-05	1998-02-19	Alfatec Pharma Gmbh	Ein Dihydropyridinderivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140191C2 (de) *	1991-12-05	1998-02-19	Alfatec Pharma Gmbh	Retardform für ein Indometacin oder Acemetacin enthaltendes Arzneimittel und seine Herstellung
DE4140184C2 (de) *	1991-12-05	1995-12-21	Alfatec Pharma Gmbh	Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140183C2 (de) *	1991-12-05	1995-12-21	Alfatec Pharma Gmbh	Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140172C2 (de) *	1991-12-05	1995-12-21	Alfatec Pharma Gmbh	Retardform für ein Ibuprofen enthaltendes Arzneimittel
CZ278863B6 (en) *	1992-09-07	1994-07-13	Galena	Medicinal preparations with n-methylated cyclic undecapeptides
KR0146671B1 (ko) *	1994-02-25	1998-08-17	김충환	사이클로스포린-함유 분말 조성물
DE4440337A1 (de) *	1994-11-11	1996-05-15	Dds Drug Delivery Services Ges	Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5766629A (en) *	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5858401A (en)	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
EP1369111A1 (de) *	1996-10-03	2003-12-10	Hermes Biosciences, Inc.	Hydrophile Mikropartikel und Verfahren zu deren Herstellung
US6249717B1 (en) *	1996-11-08	2001-06-19	Sangstat Medical Corporation	Liquid medication dispenser apparatus
US6346511B1 (en)	1997-09-08	2002-02-12	Panacea Biotec Limited	Pharmaceutical composition comprising cyclosporin
US6008191A (en) *	1997-09-08	1999-12-28	Panacea Biotec Limited	Pharmaceutical compositions containing cyclosporin
US6187747B1 (en)	1997-09-08	2001-02-13	Panacea Biotech Limited	Pharmaceutical composition comprising cyclosporin
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
DE69840586D1 (de)	1997-10-08	2009-04-02	Isotechnika Inc	Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
DE19856432A1 (de) *	1998-12-08	2000-06-15	Basf Ag	Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
US6447806B1 (en)	1999-02-25	2002-09-10	Novartis Ag	Pharmaceutical compositions comprised of stabilized peptide particles
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040121014A1 (en) *	1999-03-22	2004-06-24	Control Delivery Systems, Inc.	Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en)	1999-03-22	2001-04-17	Control Delivery Systems	Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6656504B1 (en)	1999-09-09	2003-12-02	Elan Pharma International Ltd.	Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6375972B1 (en)	2000-04-26	2002-04-23	Control Delivery Systems, Inc.	Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
DE10040707A1 (de) *	2000-08-17	2002-03-14	Braun Melsungen Ag	Kolloidale Pharmakomodulation injizierter Arzneimittel
DE60231570D1 (de)	2001-10-19	2009-04-23	Isotechnika Inc	Synthese von Cyclosporinanalogen
PT1435910E (pt) *	2001-10-19	2009-09-07	Isotechnika Inc	Novos pré-concentrados de microemulsão de análogos da ciclosporina
DE10205362A1 (de) *	2002-02-08	2003-08-21	Abbott Gmbh & Co Kg	Verfahren zur Herstellung wasserdispergierbarer Trockenpulver von in Wasser schwer löslichen Verbindungen
US8871241B2 (en) *	2002-05-07	2014-10-28	Psivida Us, Inc.	Injectable sustained release delivery devices
US7838034B2 (en)	2002-07-30	2010-11-23	Grunenthal Gmbh	Intravenous pharmaceutical form of administration
DE10234784A1 (de) *	2002-07-30	2004-02-19	Günenthal GmbH	Intravenös applizierbare, pharmazeutische Darreichungsform
WO2004071494A2 (en) *	2003-02-13	2004-08-26	Phares Pharmaceutical Research N.V.	Lipophilic compositions
US20060003002A1 (en) *	2003-11-03	2006-01-05	Lipocine, Inc.	Pharmaceutical compositions with synchronized solubilizer release
US7754243B2 (en) *	2004-08-03	2010-07-13	Clemson University Research Foundation	Aqueous suspension of nanoscale drug particles from supercritical fluid processing
DE102005011786A1 (de) *	2005-03-11	2006-09-14	Pharmasol Gmbh	Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
CA2604770C (en) *	2005-04-13	2013-09-24	Abbott Gmbh & Co. Kg	Method for carefully producing ultrafine particle suspensions and ultrafine particles and use thereof
DE102005053862A1 (de) *	2005-11-04	2007-05-10	Pharmasol Gmbh	Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
US9561178B2 (en) *	2006-07-25	2017-02-07	Allergan, Inc.	Cyclosporin compositions
WO2008058755A1 (en)	2006-11-17	2008-05-22	Abbott Gmbh & Co. Kg	Nanocrystals for use in topical cosmetic formulations and method of production thereof
DE102007001473A1 (de)	2007-01-08	2008-07-10	Andreas Lemke	Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
WO2009007992A2 (en) *	2007-04-20	2009-01-15	Sun Pharmaceutical Industries Limited	Pharmaceutical composition produced by microprecipitation
JP5149585B2 (ja) *	2007-10-02	2013-02-20	浜松ホトニクス株式会社	微粒子分散液製造方法
US20090087460A1 (en) *	2007-10-02	2009-04-02	Hamamatsu Photonics K.K.	Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
JP5161528B2 (ja) *	2007-10-02	2013-03-13	浜松ホトニクス株式会社	パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
US8861813B2 (en) *	2008-03-13	2014-10-14	Mallinckrodt Llc	Multi-function, foot-activated controller for imaging system
HU230862B1 (hu)	2008-04-28	2018-10-29	DARHOLDING Vagyonkezelő Kft	Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
DE102008037025C5 (de)	2008-08-08	2016-07-07	Jesalis Pharma Gmbh	Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
CA2785468A1 (en) *	2009-12-23	2011-06-30	Psivida Us, Inc.	Sustained release delivery devices
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
EP2583672A1 (de)	2011-10-17	2013-04-24	PharmaSol GmbH	Nanokristalle und amorphe Nanopartikel und Verfahren zur Herstellung davon mit einem Niederspannungsverfahren
WO2015071841A1 (en)	2013-11-12	2015-05-21	Druggability Technologies Holdings Limited	Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
EP3824296A4 (de)	2018-07-20	2022-04-27	Lipocine Inc.	Lebererkrankung
EP3616688A1 (de) *	2018-08-27	2020-03-04	Centre National de la Recherche Scientifique - CNRS	Herstellung von nanosuspensionshaltigen nanokristallen von pharmazeutischen wirkstoffen mit geringen oder keinen stabilisatoren

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US107288A (en) *		1870-09-13		Improvement in thread-spools
DE738604C (de) *	1935-07-09	1943-08-23	Rudolf Degkwitz Dr	Verfahren zur Herstellung von Hydrosolen mit waehlbarer Gestalt und waehlbarer Groesse der kolloiden Teilchen
JPS5831210B2 (ja) *	1973-04-09	1983-07-05	武田薬品工業株式会社	アンテイナスイセイケンダクエキノセイゾウホウ
DE2362785A1 (de) *	1973-12-18	1975-06-26	Atmos Fritzsching & Co Gmbh	Verfahren zum haltbarmachen von kristallsuspensionen
FR2257266B1 (de) *	1974-01-10	1977-07-01	Pasteur Institut
US4107288A (en) *	1974-09-18	1978-08-15	Pharmaceutical Society Of Victoria	Injectable compositions, nanoparticles useful therein, and process of manufacturing same
CA1098444A (en) *	1975-05-26	1981-03-31	Leo Geller	Peptide preparations with prolonged action
US4117118A (en) *	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
IT1142172B (it) *	1978-10-19	1986-10-08	Sandoz Ag	Nuovo impiego in terapeutica della ciclosporina-a e della diidrociclosporina-c
DE3013839A1 (de) *	1979-04-13	1980-10-30	Freunt Ind Co Ltd	Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4361580A (en) *	1980-06-20	1982-11-30	The Upjohn Manufacturing Company	Aluminum ibuprofen pharmaceutical suspensions
IT1209276B (it) *	1980-11-05	1989-07-16	Magis Farmaceutici	Composizione farmaceutica per la somministrazione orale del metilestere dell'acido 13a-etil-2,3,5,6,12,13,13a,13b-ottaidro-12-idrossi1h-indolo-[3,2,1-de] pirido [3,2,1-ij] [1,5] naftiridina -12-carbossilico
PT75550B (en) *	1981-09-22	1984-12-12	Gist Brocades Nv	Bismuth containing composition and method for the preparation thereof
GB8322364D0 (en) *	1983-08-19	1983-09-21	May & Baker Ltd	Compositions of matter
CA1239349A (en) *	1983-10-10	1988-07-19	Eberhard F. Gottwald	Pharmaceutical composition containing cimetidine
EP0138216B1 (de) *	1983-10-14	1993-01-07	Sumitomo Pharmaceuticals Company, Limited	IFN-Präparat mit verzögerter Abgabe für parentale Verabreichung
JPS60139688A (ja) *	1983-12-28	1985-07-24	Tokyo Tanabe Co Ltd	無定形ジヒドロピリジン粉末製剤
DE3347579A1 (de) *	1983-12-30	1985-07-11	Hoechst Ag, 6230 Frankfurt	Zubereitungen schwer wasserloeslicher anthelminthika und verfahren zu ihrer herstellung
CA1282405C (en) *	1984-05-21	1991-04-02	Michael R. Violante	Method for making uniformly sized particles from water-insoluble organic compounds
IE58110B1 (en) *	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
DE3515335C2 (de) *	1985-04-27	1995-01-26	Bayer Ag	Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung

1987
- 1987-12-11 HU HU875601A patent/HU205861B/hu unknown
- 1987-12-11 NL NL8702998A patent/NL194638C/nl not_active IP Right Cessation
- 1987-12-15 CH CH4885/87A patent/CH679451A5/de not_active IP Right Cessation
- 1987-12-15 DE DE3742473A patent/DE3742473C2/de not_active Expired - Lifetime
- 1987-12-17 DD DD87310651A patent/DD281344A5/de not_active IP Right Cessation
- 1987-12-17 DK DK198706641A patent/DK173319B1/da not_active IP Right Cessation
- 1987-12-17 FR FR878717792A patent/FR2608427B1/fr not_active Expired - Lifetime
- 1987-12-17 SE SE8705043A patent/SE503020C2/sv not_active IP Right Cessation
- 1987-12-17 AT AT0333087A patent/AT397914B/de not_active IP Right Cessation
- 1987-12-17 PT PT86399A patent/PT86399B/pt not_active IP Right Cessation
- 1987-12-17 LU LU87079A patent/LU87079A1/fr unknown
- 1987-12-17 NZ NZ222964A patent/NZ222964A/xx unknown
- 1987-12-17 BE BE8701461A patent/BE1000848A3/fr not_active IP Right Cessation
- 1987-12-17 GB GB8729404A patent/GB2200048B/en not_active Expired - Lifetime
- 1987-12-17 IL IL84855A patent/IL84855A/xx not_active IP Right Cessation
- 1987-12-17 CA CA000554625A patent/CA1308656C/en not_active Expired - Lifetime
- 1987-12-17 GR GR871938A patent/GR871938B/el unknown
- 1987-12-17 IE IE342587A patent/IE61179B1/en not_active IP Right Cessation
- 1987-12-18 KR KR1019870014499A patent/KR960005136B1/ko not_active Expired - Lifetime
- 1987-12-18 JP JP62322622A patent/JP2617958B2/ja not_active Expired - Lifetime
- 1987-12-18 IT IT8748729A patent/IT1230118B/it active
- 1987-12-18 MY MYPI87003217A patent/MY102037A/en unknown
- 1987-12-18 ES ES8703635A patent/ES2028492A6/es not_active Expired - Lifetime
- 1987-12-18 ZA ZA879533A patent/ZA879533B/xx unknown
1991
- 1991-01-16 US US07/642,106 patent/US5389382A/en not_active Expired - Lifetime
2000
- 2000-02-21 DK DK200000266A patent/DK173345B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2617958B2 (ja)	1997-06-11
GB2200048B (en)	1991-02-06
ZA879533B (en)	1989-08-30
HUT52941A (en)	1990-09-28
FR2608427A1 (fr)	1988-06-24
IT8748729A0 (it)	1987-12-18
DK173345B1 (da)	2000-08-07
SE8705043L (sv)	1988-06-20
MY102037A (en)	1992-02-29
BE1000848A3 (fr)	1989-04-18
DK200000266A (da)	2000-02-21
JPS63165312A (ja)	1988-07-08
PT86399B (pt)	1994-10-31
IE61179B1 (en)	1994-10-05
HU205861B (en)	1992-07-28
DK664187D0 (da)	1987-12-17
IL84855A0 (en)	1988-06-30
KR960005136B1 (ko)	1996-04-22
AU8282887A (en)	1988-06-23
NL8702998A (nl)	1988-07-18
CA1308656C (en)	1992-10-13
SE503020C2 (sv)	1996-03-11
FR2608427B1 (fr)	1991-02-08
IE873425L (en)	1988-06-19
CH679451A5 (de)	1992-02-28
NZ222964A (en)	1991-01-29
GR871938B (en)	1988-04-05
DD281344A5 (de)	1990-08-08
ATA333087A (de)	1993-12-15
PT86399A (pt)	1989-01-17
AT397914B (de)	1994-08-25
KR880007061A (ko)	1988-08-26
AU606908B2 (en)	1991-02-21
ES2028492A6 (es)	1992-07-01
DE3742473C2 (de)	1998-11-19
GB8729404D0 (en)	1988-02-03
IL84855A (en)	1992-03-29
DK664187A (da)	1988-06-20
DE3742473A1 (de)	1988-07-28
NL194638C (nl)	2002-10-04
US5389382A (en)	1995-02-14
IT1230118B (it)	1991-10-07
NL194638B (nl)	2002-06-03
GB2200048A (en)	1988-07-27
SE8705043D0 (sv)	1987-12-17
DK173319B1 (da)	2000-07-24

Publication	Publication Date	Title
BE1000848A3 (fr)	1989-04-18	Hydrosols de substances pharmacologiquement actives et compositions pharmaceutiques les contenant.
EP0766555B1 (de)	1998-12-23	Stabilisierte und unter sterilen bedingungen filtrierbare nanopartikel
BE1005236A3 (fr)	1993-06-08	Compositions pharmaceutiques a base de cyclosporines.
EP0869776B1 (de)	2004-05-06	Stabilisierte und steril filtrierbare nanopartikel
FR2636534A1 (fr)	1990-03-23	Compositions pharmaceutiques a base de cyclosporines
LU87675A1 (fr)	1991-10-08	Nouvelles compositions pharmaceutiques a base de cyclosporines
FR2675382A1 (fr)	1992-10-23	Particules des substances biologiquement actives, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2722984A1 (fr)	1996-02-02	Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
EP1523983A1 (de)	2005-04-20	Pharmazeutische Zusammensetzung enthaltend Fenofibrat und Verfahren zu deren Herstellung
LU87409A1 (fr)	1989-07-07	Nouvelle forme cristalline de la ciclosporine,sa preparation et les compositions pharmaceutiques la contenant
FR2620336A1 (fr)	1989-03-17	Utilisation de monoesters solubles dans l'eau d'acides gras comme solubilisants de medicaments
EP0282698B1 (de)	1998-10-14	Verfahren zur Herstellung eines Retardpräparates, das Diltiazem in einer einzigen Tagesdosis enthält
WO1998024430A1 (fr)	1998-06-11	Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
JP2935117B2 (ja)	1999-08-16	ナノスフェア製剤
WO2001051029A1 (fr)	2001-07-19	Composition d'itraconazole et procede de preparation
CA2182024C (fr)	2005-02-01	Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
FR2882655A1 (fr)	2006-09-08	Nouveau procede d'obtention d'une poudre d'imidapril a dissolution rapide